Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
PR Newswire
NEW YORK, Aug. 17, 2026
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.
NEW YORK, Aug. 17, 2026 /PRNewswire/ -- A revenue miss, not an earnings miss, drove Exelixis, Inc. (NASDAQ: EXEL) shares lower after the Company reported approximately $628.7 million in second-quarter revenue -- below analyst consensus -- and the stock declined. If you purchased EXEL shares and lost money, you are encouraged to submit your losses for review now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Adjusted earnings came in at $0.91 per share, above estimates. The market reaction went the other way: coverage of the report identified the top-line shortfall against consensus -- not profitability -- as the driver of the decline. Exelixis also lowered and narrowed its full-year 2026 revenue outlook alongside the results, attributing the change to a slower-than-expected ramp in its neuroendocrine-tumor business.
Levi & Korsinsky is investigating potential securities law violations on behalf of Exelixis investors who suffered losses in connection with the Company's second-quarter results and the revised revenue outlook.
Shareholders who lost money on EXEL are encouraged to have their claim evaluated at no cost , or call (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the EXEL Investigation
Q: How much did EXEL stock drop? A: Shares declined approximately 7.9% after Exelixis reported approximately $628.7 million in second-quarter revenue, below Wall Street consensus, and lowered and narrowed its full-year 2026 revenue outlook. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Who is eligible to participate in the EXEL investigation? A: Investors who purchased EXEL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What is the EXEL securities investigation about? A: A securities investigation is pending concerning Exelixis, Inc. (NASDAQ: EXEL) regarding potentially materially false or misleading statements. Shares fell after the Company reported second-quarter revenue below consensus and reduced its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp.
Q: What do EXEL investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my EXEL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EXEL and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE Levi & Korsinsky, LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States